Meeting
2022 ASCO Annual Meeting
Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from JAVELIN Bladder 100 in subgroups defined by response to 1L chemotherapy.
Authors
Begoña Pérez-Valderrama
Hospital Universitario Virgen del Rocío, Seville, Spain
Begoña Pérez-Valderrama , Thomas Powles , Srikala S. Sridhar , Claudia Caserta , Yohann Loriot , Shilpa Gupta , Joaquim Bellmunt , Cora N. Sternberg , Jing Wang , Nuno Costa , Robert J Laliberte , Alessandra Di Pietro , Se Hoon Park , Petros Grivas
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Urothelial Cancer - Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT02603432
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 4559)
DOI
10.1200/JCO.2022.40.16_suppl.4559
Abstract #
4559
Poster Bd #
50
Abstract Disclosures
Similar Posters
Poster
2021 Genitourinary Cancers Symposium
Avelumab (Ave) first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): JAVELIN Bladder 100 subgroup analysis based on duration and cycles of 1L chemotherapy.
First Author: Yohann Loriot
Poster
2023 ASCO Genitourinary Cancers Symposium
Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Long-term follow-up from the JAVELIN Bladder 100 trial in subgroups defined by 1L chemotherapy regimen and analysis of overall survival (OS) from start of 1L chemotherapy.
First Author: Srikala S. Sridhar
Poster
2021 ASCO Annual Meeting
Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC) in the JAVELIN Bladder 100 trial: Subgroup analysis by duration of treatment-free interval (TFI) from end of chemotherapy to start of maintenance.
First Author: Srikala S. Sridhar
Poster
2021 ASCO Annual Meeting
Avelumab first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): Analysis of time to end of next-line therapy in JAVELIN Bladder 100.
First Author: Petros Grivas